HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer - Summary - MDSpire
From the Journals
Clinical Guidelines

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

The addition of the selective HER2 inhibitor tucatinib to trastuzumab and pertuzumab as first-line maintenance therapy significantly prolonged investigator-assessed progression-free survival in patien...

Share

The HER2CLIMB-05 study showcased that adding tucatinib to trastuzumab and pertuzumab significantly enhances progression-free survival in HER2-positive metastatic breast cancer patients undergoing first-line maintenance therapy. This randomized phase III trial demonstrated an absolute improvement of 8.6 months in progression-free survival, regardless of hormone receptor status or brain metastases, while maintaining a manageable safety profile. The findings were presented at SABCS 2025 and published in the Journal of Clinical Oncology.

Original Source(s)

HER2CLIMB-05 Study: Tucatinib Enhances Progression-Free Survival as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

  • by The ASCO Post Staff

  • April 3, 2026

Related Content

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individ...

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

The CAR T-cell therapy brexucabtagene autoleucel (Tecartus) was issued full approval for adult patients with relapsed or refractory mantle cell lymphoma (MCL). The approval now includes efficacy, safe...

Turning Proteins into DNA for Ultra-Sensitive Sequencing

Stanford researchers repurpose DNA sequencing technology to read proteins at single-molecule resolution, complementing – and potentially surpassing – mass spectrometry

  • April 2, 2026

  • 2 min